|
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Jun 2023
|
Blood
|
aplastic anemia
|
|
Recent developments in myelodysplastic syndromes
|
Sep 2014
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
|
Sep 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Stem and progenitor cell alterations in myelodysplastic syndromes
|
Feb 2017
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
How I Treat Paroxysmal nocturnal hemoglobinuria
|
Jan 2021
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia
|
Oct 2014
|
Blood
|
aplastic anemia
|
|
Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
|
May 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Newly revised 2023 MDS response criteria
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Cyclophosphamide in severe aplastic anemia?
|
Oct 2014
|
Blood
|
aplastic anemia
|
|
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
|
Apr 2023
|
Blood
|
myelodysplastic syndromes (MDS)
|
